oa Mass Spectrometry in Covalent Drug Discovery

References

1. BoikeL. HenningN.J. NomuraD.K. Advances in covalent drug discovery.Nat. Rev. Drug Discov.2022211288189810.1038/s41573‑022‑00542‑z36008483
   [Google Scholar]
2. LanmanB.A. AllenJ.R. AllenJ.G. AmegadzieA.K. AshtonK.S. BookerS.K. ChenJ.J. ChenN. FrohnM.J. GoodmanG. KopeckyD.J. LiuL. LopezP. LowJ.D. MaV. MinattiA.E. NguyenT.T. NishimuraN. PickrellA.J. ReedA.B. ShinY. SiegmundA.C. TamayoN.A. TegleyC.M. WaltonM.C. WangH.L. WurzR.P. XueM. YangK.C. AchantaP. BartbergerM.D. CanonJ. HollisL.S. McCarterJ.D. MohrC. RexK. SaikiA.Y. San MiguelT. VolakL.P. WangK.H. WhittingtonD.A. ZechS.G. LipfordJ.R. CeeV.J. Discovery of a covalent inhibitor of KRAS G12C (AMG 510) for the treatment of solid tumors.J. Med. Chem.2020631526510.1021/acs.jmedchem.9b0118031820981
   [Google Scholar]
3. OwenD.R. AllertonC.M.N. AndersonA.S. AschenbrennerL. AveryM. BerrittS. BorasB. CardinR.D. CarloA. CoffmanK.J. DantonioA. DiL. EngH. FerreR. GajiwalaK.S. GibsonS.A. GreasleyS.E. HurstB.L. KadarE.P. KalgutkarA.S. LeeJ.C. LeeJ. LiuW. MasonS.W. NoellS. NovakJ.J. ObachR.S. OgilvieK. PatelN.C. PetterssonM. RaiD.K. ReeseM.R. SammonsM.F. SathishJ.G. SinghR.S.P. SteppanC.M. StewartA.E. TuttleJ.B. UpdykeL. VerhoestP.R. WeiL. YangQ. ZhuY. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19.Science202137465751586159310.1126/science.abl478434726479
   [Google Scholar]
4. SutantoF. KonstantinidouM. DömlingA. Covalent inhibitors: A rational approach to drug discovery.RSC Medicinal Chemistry202011887688410.1039/D0MD00154F33479682
   [Google Scholar]
5. LvZ. YuanL. AtkisonJ.H. WilliamsK.M. VegaR. SessionsE.H. DivlianskaD.B. DaviesC. ChenY. OlsenS.K. Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme.Nat. Commun.201891514510.1038/s41467‑018‑07015‑130514846
   [Google Scholar]
6. OlpM.D. SpragueD.J. GoetzC.J. KathmanS.G. Wynia-SmithS.L. ShishodiaS. SummersS.B. XuZ. StatsyukA.V. SmithB.C. Covalent-fragment screening of BRD4 identifies a ligandable site orthogonal to the acetyl-lysine binding sites.ACS Chem. Biol.20201541036104910.1021/acschembio.0c0005832149490
   [Google Scholar]
7. KlüterS. SimardJ.R. RodeH.B. GrütterC. PawarV. RaaijmakersH.C.A. BarfT.A. RabillerM. van OtterloW.A.L. RauhD. Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: A tool for dissecting kinase drug resistance.ChemBioChem201011182557256610.1002/cbic.20100035221080395
   [Google Scholar]
8. JohanssonH. Isabella TsaiY.C. FantomK. ChungC.W. KümperS. MartinoL. ThomasD.A. EberlH.C. MuelbaierM. HouseD. RittingerK. Fragment-based covalent ligand screening enables rapid discovery of inhibitors for the RBR E3 ubiquitin ligase HOIP.J. Am. Chem. Soc.201914162703271210.1021/jacs.8b1319330657686
   [Google Scholar]
9. CampuzanoI.D.G. San MiguelT. RoweT. OneaD. CeeV.J. ArvedsonT. McCarterJ.D. High-throughput mass spectrometric analysis of covalent protein-inhibitor adducts for the discovery of irreversible inhibitors: A complete workflow.SLAS Discov.201621213614410.1177/108705711562128826676098
   [Google Scholar]
10. ShinY. JeongJ.W. WurzR.P. AchantaP. ArvedsonT. BartbergerM.D. CampuzanoI.D.G. FuciniR. HansenS.K. IngersollJ. IwigJ.S. LipfordJ.R. MaV. KopeckyD.J. McCarterJ. San MiguelT. MohrC. SabetS. SaikiA.Y. SawayamaA. SethoferS. TegleyC.M. VolakL.P. YangK. LanmanB.A. ErlansonD.A. CeeV.J. Discovery of N -(1-Acryloylazetidin-3-yl)-2-(1 H -indol-1-yl)acetamides as covalent inhibitors of KRAS G12C.ACS Med. Chem. Lett.20191091302130810.1021/acsmedchemlett.9b0025831531201
    [Google Scholar]
11. LangrishC.L. BradshawJ.M. FrancescoM.R. OwensT.D. XingY. ShuJ. LaStantJ. BisconteA. OuterbridgeC. WhiteS.D. HillR.J. BrameldK.A. GoldsteinD.M. NunnP.A. Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease.J. Immunol.202120671454146810.4049/jimmunol.200113033674445
    [Google Scholar]
12. PuF. KniznerK.T. RobeyM.T. RadosevichA.J. UgrinS.A. ElsenN.L. DurbinK.R. WilliamsJ.D. High-throughput deconvolution of intact protein mass spectra for the screening of covalent inhibitors.J. Am. Soc. Mass Spectrom.202233122338234110.1021/jasms.2c0027336378849
    [Google Scholar]
13. ZhangH. LiuC. HuaW. GhislainL.P. LiuJ. AschenbrennerL. NoellS. DiricoK.J. LanyonL.F. SteppanC.M. WestM. ArnoldD.W. CoveyT.R. DatwaniS.S. TroutmanM.D. Acoustic ejection mass spectrometry for high-throughput analysis.Anal. Chem.20219331108501086110.1021/acs.analchem.1c0113734320311
    [Google Scholar]
14. LiuC. Van BerkelG.J. KovarikP. PerotJ.B. InguvaV. CoveyT.R. Fluid dynamics of the open port interface for high-speed nanoliter volume sampling mass spectrometry.Anal. Chem.202193248559856710.1021/acs.analchem.1c0131234110783
    [Google Scholar]
15. WenX. Ultra-high-throughput intact protein analysis for drug discovery using acoustic ejection mass spectrometryASMS 2023Houston, TX2023
    [Google Scholar]